Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPATential150: Ipatasertib + Abiraterone in mCRPC
NCT03072238Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of ipatasertib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Roche. Started Jun 2017; status: completed.
02
Drugs
ipatasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03072238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03072238.